Orphanet Journal of Rare Diseases (Mar 2020)

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

  • Mercedeh Ghadessi,
  • Rui Tang,
  • Joey Zhou,
  • Rong Liu,
  • Chenkun Wang,
  • Kiichiro Toyoizumi,
  • Chaoqun Mei,
  • Lixia Zhang,
  • C. Q. Deng,
  • Robert A. Beckman

DOI
https://doi.org/10.1186/s13023-020-1332-x
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs.

Keywords